Amgen's ‘Neulasta’ market enters into competition system

Published: 2014-08-20 09:59:53

Updated: 2014-08-20 10:00:41

Amgen's mega blockbuster biopharmaceutical Neulasta (neutropenia treatment) market enters into competition system, because domestic top pharmaceutical companies also received final approval of biobetter recently.

Representative neutropenia treatment 'Neulasta' is for the treatment of febrile neutropenia (a type of white blood cells), and recorded sales of about 6 trillion won in worldwide, inc...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.